FDA approval for Crosslinking for keratoconus

I was invited by Eyeworld Asia-Pacific to comment on the various opinions of surgeons on crosslinking for keratoconus and its recent FDA approval. Keratoconus is a progressive degenerative condition of the cornea which affects mainly teenagers and young adults. It is the most common reason for a corneal transplant in Australia and New Zealand. Crosslinking is a treatment that stops the deterioration and has been shown to reduce the number of young people needing a transplant for this sight threatening condition. I have been performing crosslinking since 2006.